MODERATE TO SEVERE PLAQUE PSORIASIS
Clinical trials for MODERATE TO SEVERE PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New psoriasis shot shows promise in early safety trial
Disease control CompletedThis early-stage study tested a new drug called SHR-1139 in 64 people. First, healthy volunteers received a single shot or IV dose to check safety. Then, patients with moderate-to-severe plaque psoriasis got multiple shots. The main goal was to see if the drug is safe and how the…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 17, 2026 06:21 UTC
-
New psoriasis drug shows promise in Head-to-Head trial
Disease control CompletedThis study tested a new drug called bimekizumab against an existing treatment (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% clearer skin after 16 weeks of treatment. The trial also looked at lon…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief CompletedThis study tested an experimental drug called SCD-044 in 263 adults with moderate to severe plaque psoriasis. The goal was to see if the drug could improve skin symptoms like redness and scaling better than a placebo. The trial was completed and used a double-blind design, meanin…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE2 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC
-
Real-World data shows how long patients stay on secukinumab for skin and joint conditions
Knowledge-focused CompletedThis study followed 127 adults with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis for 2 years to see how long they stayed on secukinumab treatment and how their quality of life changed. Researchers co…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 01, 2026 15:57 UTC